retatrutide phase 2 nejm weight loss 48 weeks triple agonist First-in-Class 'Triple-G'! Retatrutide, a first-in-class GIP, GLP-1 & Glucagon hormone receptor drug leads to nearly 29% in first pivotal test! Eli Lilly announced positive topline results from the This data from Phase 3
Pay in 4 interest-free payments of $6.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31























